Merck seeks GLP-1 drugs with benefits beyond weight loss - CEO

Merck & Co (MRK.N) is seeking GLP-1 treatments with benefits beyond weight loss, CEO Robert Davis said on Thursday at a conference.

Newer diabetes and weight-loss drugs of the GLP-1 class like Novo Nordisk's (NOVOb.CO) Wegovy and Ozempic and Eli Lilly's (LLY.N) Mounjaro and Zepbound are expected to together generate annual sales of over $100 billion by the end of the decade.